Glenn M. Chertow

Jan 10, 2025 | digitalcommons.library.tmc.edu | Wolfgang C. Winkelmayer |Susan Arnold |Steven Burke |Glenn M. Chertow

RATIONALE & OBJECTIVE: Prespecified analyses of the PROSTUDY DESIGN: Phase 3, global, open-label, randomized, active-controlled clinical trial. SETTING AND PARTICIPANTS: Erythropoiesis-stimulating agent-untreated patients with anemia and NDD-CKD. INTERVENTION: Eligible patients were randomized 1:1 to receive vadadustat or darbepoetin alfa. OUTCOMES: The primary safety end point was time to first MACE.

Nov 4, 2024 | acsjournals.onlinelibrary.wiley.com | David Lim |Maria E. Montez-Rath |Glenn M. Chertow |Benjamin Chung

Background Prostate cancer is the most common cancer among men in the United States, yet modifiable risk factors remain elusive. In this study, the authors investigated the potential role of agricultural pesticide exposure in prostate cancer incidence and mortality.

Mar 17, 2023 | exbulletin.com | Glenn M. Chertow

Data from a phase 2a trial investigating the use of inaxaplin suggest that small molecule APOL1 Inhibitors are Focal segmental glomerulosclerosis (FSGS) and 2 APOL1 variant.